Potentially modifiable factors to reduce severity of COVID-19 in type 2 diabetes

Nikhil V. Dhurandhar1, Md Akheruzzaman1 and Vijay Hegde1

COVID-19 pandemic, diabetes, and obesity

Since December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or CoV-2) disease (COVID-19) pandemic has claimed over 517,610 lives worldwide, among which 128,184 are from the US1. The appearance, severity, prognosis, and case fatality of COVID-19 is disproportionately higher in people with pre-existing obesity, type 2 diabetes (T2D) and other cardio-metabolic diseases, and in people of racial and ethnic minorities2. Furthermore, COVID-19-related damage of the heart and kidneys is greater in the presence of T2D3–5, which itself is a major risk factor for cardiovascular disease6 and end-stage renal disease (CKD)7,8. This is of serious concern for the United States, where two out of three adults have higher body weight, and ~42% have obesity, and the prevalence of obesity is 85% and 30–60% in T2D and hypertension, respectively9.

Without effective vaccines or therapies for the prevention or treatment of CoV-2 infection at this time, there is an urgent need for strategies to at least minimize COVID-19-related comorbidities or fatalities. In particular, considering the disproportionately higher COVID-19-related mortality in people with obesity, T2D, and other cardio-metabolic diseases, we wish to share a viewpoint about the possible steps to take, which may save lives.

It is unclear why COVID-19 causes disproportionately more severe symptoms and complications in people with obesity and those with hypertension or T2D. The synergistic stress of acute respiratory distress syndrome and pre-existing obesity and its comorbidities may provide a likely explanation. Here, we wish to outline a possibility related to the negative interaction of CoV-2 and certain anti-diabetic medications, that deserves serious consideration.

The selective high-risk of COVID-19 with obesity, may stem from its very fundamental mechanism of infection. CoV-2 exploits the angiotensin-converting enzyme (ACE)-2 receptor for cellular entry10,11. Overexpression of ACE2 can facilitate CoV-2 entry and subsequent severity of infection12. CoV-2 virus has a particular affinity for lung cells (airway epithelial cells)12. Besides the lung cells, ACE2 is expressed in many cell types, including adipocytes, renal cells, and cardiomyocytes. Although people with obesity do not overexpress ACE213, more cells with ACE2 will be present in individuals with obesity (greater number of adipocytes), which may support greater virus replication and infection. This may be a reason for worse outcome of CoV-2 infection for people with obesity. Intuitively, fat loss appears as an approach to counter worse outcome of CoV-2 infection in obesity. However, a quick induction of fat loss is less likely in COVID-19 patients. Instead, it may be more pragmatic to focus on comorbidities of obesity such as T2D during COVID-19.

At least three key factors that distinguish individuals with obesity and T2D from individuals without such conditions are, greater circulating levels of glucose, inflammatory cytokines, and the use of anti-diabetic drugs. These factors are linked with ACE2 expression or activity, which may in turn, influence the severity of CoV-2 infection. High blood glucose alone can increase the expression and enzymatic activity of ACE2 in cells14–16. Inflammatory cytokines like tumor necrosis factor-α, interferon-γ, or interleukin-6, are increased in T2D. It is unclear if these cytokines facilitate CoV-2 entry or oppose it, as they have been reported to increase17 or decrease ACE2 expression18. In addition, the increased risk of COVID-19 for people with T2D may in part, be iatrogenic. Some anti-diabetic drugs such as those from groups, including PPARγ agonists, SGLT2 inhibitors or GLP1 receptor agonists upregulate ACE2 expression in
rodent model or cells, whereas some do not (metformin, insulin)\(^9\) or have not yet been tested for their effect on ACE2. The drugs that upregulate ACE2 expression may inadvertently facilitate CoV-2 infection in humans, leading to an increase in disease severity and consequential mortality. Some reports suggest the use of PPAR-\(\gamma\) agonist agents, such as pioglitazone in COVID-19 patients to reduce pulmonary fibrosis and inflammation\(^{20,21}\). Although, the anti-fibrotic and anti-inflammatory properties of PPAR-\(\gamma\) agonists are attractive, their role in ACE2-mediated entry of CoV-2 needs further examination. Based on the current information, we postulate that in T2D, the role of these three factors should be studied for their individual and/or collective effect on ACE-2 expression, binding of CoV-2 to the receptor, and COVID-19 severity.

**Guidance needed**

Owing to the urgency for information, there is a scramble to issue clinical guidelines based on observational information, for the management of hyperglycemia, inflammation, and use of anti-diabetic medication during CoV-2 infection for T2D patients with other comorbidities\(^{22}\). However, experimental, cell-based or animal evidence to guide these clinical decisions is needed.

This is particularly important as the interaction of a drug may be different in the presence of CoV-2 infection. For example, increasing ACE2 expression by a therapeutic agent may be desirable in T2D management\(^{23}\), but may be detrimental in the presence of COVID-19. Hydroxychloroquine is an example of why experimental evidence is necessary, even for intuitive sounding solutions. It is a normally useful drug for malaria, that was highly touted for COVID-19 treatment, but failed to treat COVID-19\(^{24,25}\) and in fact increased mortality in the presence of CoV-2 infection\(^{26}\).

Generating underlying mechanistic evidence can increase confidence in the accuracy of these guidelines or may provide the opportunity for a course correction. For example, the worse outcome of COVID-19 in diabetes may in part be of iatrogenic origin. Perhaps, the drugs that upregulate ACE2 expression, inadvertently facilitate CoV-2 infection, leading to greater severity and mortality. Identification of anti-diabetic drugs that do not promote ACE-2 expression or increase COVID-19 severity may provide better clinical choices for treating T2D patients with COVID-19. Similarly, COVID-19 invokes a response of inflammatory cytokines, known as cytokine storms\(^{27}\). Clinical efforts are directed towards reducing this systemic inflammatory response. However, it would be important to determine the effect of cytokine storm or its treatment on ACE-2 expression and CoV-2 binding.

**Conclusions**

Severity and mortality of COVID-19 caused by the CoV-2 virus, is greater in people with obesity, hypertension, and diabetes. While there may be many known or unknown factors contributing to this phenomenon, here we focus on one specific possibility. Worse outcome of COVID-19 in diabetes may in part be of iatrogenic origin. Angiotensin-converting enzyme-2 (ACE2) acts as a receptor for cellular entry of CoV-2. Some, but not all anti-diabetic drugs upregulate ACE2 expression, which further can be modulated in the presence of high level of glucose and inflammatory cytokines. Perhaps, the drugs that upregulate ACE2 expression, inadvertently facilitate CoV-2 infection, leading to greater severity and mortality. We urge research to identify the anti-diabetic drugs that do or do not facilitate CoV-2 entry in cells, and to determine their anti-diabetic efficacy in COVID-19. This could help replace anti-diabetic medications that promote CoV-2 entry in cells with alternatives that do not, and yet are effective. While the obesity status of COVID-19-infected individuals cannot be changed rapidly, medications for their diabetes management can promptly be switched to an optimal option, which may save many lives.

**Conflict of interest**

The authors declare that they have no conflict of interest.

**Publisher’s note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 7 June 2020 Revised: 9 July 2020 Accepted: 30 July 2020

Published online: 12 August 2020

**References**

1. John Hopkins University and Medicine Coronavirus Resource Center. [https://coronavirus.jhu.edu/](https://coronavirus.jhu.edu/) (John Hopkins University, 2020).
2. Bode, B. et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. *J Diabetes Sci Technol.* **14**, 813–821 (2020).
3. Damman, K. et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. *Eur. Heart J.* **35**, 455–469 (2014).
4. Dei-Cas, A. et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. *JACC Heart Fail* **3**, 136–145 (2015).
5. Lofman, I. et al. Prevalence and prognostic impact of kidney disease on heart failure patients. *Open Heart* **3**, e000324 (2016).
6. Grundy, S. M. et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. *Circulation* **100**, 1134–1146 (1999).
7. Ismail, N. et al. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. *Kidney Int.* **55**, 1–28 (1999).
8. Vermeing, L. J. et al. The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM. *Clin. Nephrol.* **51**, 133–140 (1999).
9. Carp, R. I. et al. Preclinical changes in weight of scrapie-infected mice as a function of scrapie agent-mouse strain combination. *Interwetolog* **21**, 61–69 (1984).
10. Patel, A. B. & Verma, A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? *JAMA* **323**, 1769–1770 (2020).
11. Diaz, J. H. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J. Travel Med. 27 (2020).

12. Jia, H. P. et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J. Virol. 79, 14614–14621 (2005).

13. Pinheiro, T. A. et al. Obesity and malnutrition similarly alter the renin-angiotensin system and inflammation in mice and human adipose. J. Nutr. Biochem. 48, 74–82 (2017).

14. Coelho, M. S. et al. High sucrose intake in rats is associated with increased ACE2 and angiotensin-(1–7) levels in the adipose tissue. Regulatory Pept. 162, 61–67 (2010).

15. Härdtner, C. et al. High glucose activates the alternative ACE2/Ang-(1–7)/Mas and APN/Ang II/MRAP RAS axes in pancreatic β-cells. Int. J. Mol. Med. 32, 795–804 (2013).

16. Lavrentyev, E. N., Estes, A. M. & Malik, K. U. Mechanism of high glucose-induced angiotensin II production in rat vascular smooth muscle cells. Circulation Res. 101, 455–464 (2007).

17. Ziegler, C. G. K. et al. SARS-CoV-2 Receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181, 1016–1035 (2020).

18. de Lang, A., Osterhaus, A. D. M. E. & Haagmans, B. L. Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. Virology 353, 474–481 (2006).

19. Pal, R. & Bhadada, S. K. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Res. Clin. Pr. 163, 108146 (2020).

20. Kruglikov, I. L. & Scherer, P. E. The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections. Obesity 28, 1187–1190 (2020).

21. Carboni, E., Carta, A. R. & Carboni, E. Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19? Med. Hypotheses 140, 109776 (2020).

22. Bornstein, S. R. et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 8, 546–550 (2020).

23. Battle, D., Jose Soler, M. & Ye, M. ACE2 and diabetes: ACE of ACEs? Diabetes 59, 2994–2996 (2010).

24. Geleris, J. et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl. J. Med. 382, 2411–2418 (2020).

25. Rosenberg, E. S. et al. Association of treatment with hydroxychloroquine or azithromycin with in-Hospital mortality in patients with COVID-19 in New York State. JAMA 323, 2493–2502 (2020).

26. Magagnoli, J. et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. N Engl. J. Med. 382, 2411–2418 (2020).

27. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (Lond, Engl.) 395, 497–506 (2020).